PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Medicine, University College London, London, UK. Electronic address: D.gilroy@ucl.ac.uk.\', \'Division of Medicine, University College London, London, UK.\', \'Senex Therapeutics Inc., Newton, Center, MA, USA.\', \'Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Sweden.\', \'Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0163-7258(20)30276-X10.1016/j.pharmthera.2020.107745
?:hasPublicationType
?:journal
  • Pharmacology & therapeutics
is ?:pmid of
?:pmid
?:pmid
  • 33188794
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33188794>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33188794>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all